Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | CES2 | O00748 | 13/20 | 0.52 |
| ▸ | CES1 | P23141 | 12/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzil SCHEMBL8695965 | 0.82 | CES2 (0.56) | RAB9ACES2CES1HPGDEGFR | |
| SCHEMBL3829873 | 0.82 | RAB9A (0.71) | RAB9ACES2CES1HPGDNPC1 | |
| SCHEMBL14982110 | 0.80 | RAB9A (0.63) | RAB9ACES2CES1HPGDNPC1 | |
| SCHEMBL3828550 | 0.80 | RAB9A (0.54) | RAB9ACES2CES1HPGDNPC1 | |
| SCHEMBL3572173 | 0.79 | TSHR (0.45) | ALDH1A1MAPT | |
| SCHEMBL4140401 | 0.77 | RAB9A (1.00) | RAB9ACES2CES1HPGDNPC1 | |
| Benzil SCHEMBL4356607 | 0.77 | CES2 (0.61) | RAB9ACES2CES1HPGDEGFR | |
| SCHEMBL30671562 | 0.76 | RAB9A (0.96) | RAB9ACES2CES1HPGDNPC1 | |
| Benzil SCHEMBL4351569 | 0.75 | CES2 (0.64) | RAB9ACES2CES1HPGDEGFR | |
| SCHEMBL14982120 | 0.75 | CES2 (0.68) | RAB9ACES2CES1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999835-B1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | TAIJI BIOMEDICAL INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |